A real-world prospective multicenter study to evaluate the safety and effectiveness of Dydrogesterone in endometriosis

Zydus Healthcare Limited0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年8月19日

试验速览

暂无简介。

•1. Female, aged = 18 years and = 45 years.
•2. Complaints on chronic pelvic pain with or without dysmenorrhea assessed by 11-items NRS.
•3. External genital endometriosis confirmed by clinical evaluation, or imaging analysis (ultrasonography) of endometriotic ovarian chocolate cysts.
•4. Eligible to be prescribed treatment with dydrogesterone according to labeling for treatment of endometriosis.
•5. No hormonal treatment in 2 cycles before enrolment.
•6. Willing to provide written informed consent

•1. Routine consumption of analgesics other than for the pain of endometriosis.
•2. Patients receiving hormonal contraceptives in the last 2 cycles (including intrauterine devices, contraceptive patches, contraceptive rings, oral contraceptives, etc.).
•3. Ongoing pregnancy.
•4. Contraindications to dydrogesterone listed in the locally approved label
•5. Any other condition that precludes the use of dydrogesterone in accordance with the precautions and special warnings listed in the locally approved label
•6. Other conditions that made the patient’s participation impossible (based on the investigator’s decision).
•7. Fertility treatments using assisted reproductive technology

发起方